Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer seeks FDA blessing for COVID-19 vaccine booster

The regulatory agency had approved the Pfizer-BioNTech vaccine on August 23.

By Brian Buntz | August 25, 2021

Pfizer-BioNTechPfizer (NYSE:PFE) and its partner BioNTech SE (NSDQ:BNTX) aim to expand the recent FDA approval of their COVID-19 vaccine to include booster doses for individuals 16 and older.

The companies have submitted a supplemental Biologics License Application to the FDA, including Phase 3 data drawn from participants aged 15 to 55.

The latest data indicate that a third dose of the Comirnaty vaccine boosts antibody titers and continues to be well tolerated.

Trial investigators administered the booster between 4.8 and 8 months after giving the second dose of the COVID-19 vaccine.

The booster resulted in strong protection against the original or wild-type strain of SARS-CoV-2. Specifically, 99.5% of participants had a four-fold increase in neutralizing antibody levels after the third dose.

The most common side effects were similar to those from earlier doses, including injection-site soreness, fatigue, headache, muscle aches and chills.

The companies had announced on August 16 that they had submitted Phase 1 data to the FDA related to vaccine boosters.

Pfizer and BioNTech also plan to submit the latest data to the European Medicines Agency in the coming weeks.

Not included in the most recent press release was mention of the Delta variant. However, Phase 1 data suggests that a booster dose offers substantially improved protection against Delta, which is now responsible for 98.8% of U.S. infections, according to CDC.

The company is also developing a Delta-specific version of its vaccine and had projected that clinical trials for the modified vaccine would begin this month, subject to regulatory authorization.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, Comirnaty, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-moleĀ 
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50